Google
KLRA — KAILERA THERAPEUTICS, INC. COMMON STOCK (Healthcare >> Biotechnology)
KLRA FAQ
What is KLRA's ROE?
KAILERA THERAPEUTICS, INC. COMMON STOCK reports a Return on Equity (ROE) of 22.41%.
What is KLRA's dividend yield?
KAILERA THERAPEUTICS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is KLRA's Deepscope Quality Score?
Deepscope rates KLRA's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KLRA?
Deepscope's AI Timing Score for KLRA is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KLRA belong to?
KAILERA THERAPEUTICS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 19.37
Price
-1.62
(-7.72%)
Day Change
|
|
|---|
KLRA, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.16 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 19.37 |
| PBV / Sector |
-6.71 / 4.63
|
| Earning Per Share | -0.65 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
8.90 M
|
| Average 1W Daily Value |
9.04 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:48 |
| Symbol | KLRA |
| Name | KAILERA THERAPEUTICS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 129.57 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,899.68 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 180 Third Avenue, Waltham, MA, United States, 02451
Phone: 781 317 0290
Website: https://www.kailera.com
Employees: 145
Sector: Healthcare >> Biotechnology
Description: Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
